Search results
Showing 1 to 50 of 8117 results
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer
Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing
Find out more about NICE's new proportionate approach to technology appraisals
Our board sets out our strategic priorities and policies.
NICE research projects and partners.
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults.
Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE in final draft guidance.
Recommendation ID IPG779 Question Middle meningeal artery embolisation for chronic subdural haematomas should be used only in research
Recommendation ID NG238/3 Question What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes
What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris?
Recommendation ID NG198/8 Question What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris? Any explanatory
Recommendation ID NG198/2 Question What is the most effective first-line treatment option for any severity of acne vulgaris for people
What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?
Recommendation ID NG198/1 Question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Any
What is the effect of dietary interventions or dietary changes on acne?
Recommendation ID NG198/3 Question What is the effect of dietary interventions or dietary changes on acne? Any explanatory notes(if
What are the risk factors for acne vulgaris-related scarring?
Recommendation ID NG198/6 Question What are the risk factors for acne vulgaris-related scarring? Any explanatory notes(if applicable)
What information and support is valued by people with acne vulgaris?
Recommendation ID NG198/9 Question What information and support is valued by people with acne vulgaris? Any explanatory notes(if
Recommendation ID NG238/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the
Recommendation ID NG198/4 Question What skin care advice is appropriate for people with acne? Any explanatory notes(if applicable)
What is the effectivness of statin treatment in older people?
Recommendation ID NG238//2 Question What is the effectivness of statin treatment in older people? Any explanatory notes(if applicable)
Recommendation ID NG51/6 Question In adults and young people (16 and over) with suspected sepsis in acute hospital settings, ambulance
Recommendation ID NG198/5 Question What is the effectiveness of physical treatments (such as light devices) in the treatment of acne vulgaris
Recommendation ID NG198/7 Question What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke
Our indicators measure outcomes that reflect quality of care. They also look at processes that are linked by evidence to improved outcomes. All our...
Our board sets out our strategic priorities and policies. The day to day decision-making is the responsibility of our executive team . The...
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Tell us about an interventional procedure you think should be assessed by NICE.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....
View recommendations for HTE18Show all sections
Embed NICE content in your digital products and services with our syndication API
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.
Our methods and processes (health technology evaluation manual)
Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...
Costs: charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS. Browse technology...
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
NICE executive team meeting minutes and agenda
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA966
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients.